Back to all Programs

Past Event

Related Materials

Past Event

Spanish HIV Clinical Forum 2017

Update on HIV Transmitted and Acquired Integrase Resistance in Spain - Relevance to Routine Clinical Practice- Federico García, MD

Prevalence of Transmitted Drug Resistance Mutations among Naïve HIV-infected patients (2014-2016) in Northwest Spain- B. Pernas Souto

2016-2017 - Key Advances in HIV Treatment- José Arribas, MD

Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016 - M. Casadellà

Mutaciones a Inhibidores de la Integrasa en la vida real- I. Viciana

Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. Viciana

Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MD

Pharmacological perspective- José Moltó, MD, PhD

Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD

Virological perspective- Santiago Moreno, MD

Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD

HIV Prevention 2.0- Charles Boucher, MD, PhD

Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos

Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano

Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. Montejano

Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-Torres

Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. Mur

PrEP and prevention- Pep Coll, MD